$OSTX News

OS Therapies Announces Initial Closing of Warrant Exercise Inducement and Exchange Offer for Initial Gross Proceeds of Approximately $7.2 Million

Rubenstein Public Relations Named Agency of Record for OS Therapies

OS Animal Health Receives USDA Feedback on Regulatory Pathway for OST-HER2 in Canine Osteosarcoma

OS Therapies' OSAH Subsidiary Receives U.S. Department Of Agriculture Guidance On Commercial Deployment Pathway For OST-HER2 To Treat Canine Osteosarcoma

OS Therapies Reports Significant Three-Year Survival Data for Bone Cancer Treatment

OS Therapies Achieves Statistically Significant Final Three-Year Overall Survival Benefit for Herlystic(TM)-Treated Patients in Phase 2b Pulmonary Metastatic Osteosarcoma Trial

OS Therapies Announces Statistically Significant Final 3-Yr Overall Survival Benefit For OST-HER2-Treated Patients In Phase 2b Trial In Pulmonary Metastatic Osteosarcoma Compared With Combined Published Historical Control

OS Therapies Appoints Kerry Clem as Chief Commercial Officer and Frank Knuettel II as Chief Financial Officer

OS Therapies Appoints Frank Knuettel II As CFO

OS Therapies Announces Brand Name 'Herlystic' Approved by World Health Organization for OST-HER2 (daznelimgene lisbac)

OS Therapies Completes FDA Type C Statistical Methods Meeting and Provides Update on Global Regulatory Coordination for OST-HER2 Under Project Orbis

OS Therapies Provided an Update on Global Early Market Access Regulatory Coordination Efforts By UK's MHRA For OST-HER2 For Pulmonary Metastatic Osteosarcoma Under Project Orbis

OS Therapies Achieves Incremental Alignment With FDA and Accepts Project Orbis Invitation From MHRA on OST-HER2 Metastatic Osteosarcoma Program

OS Therapies Achieves Incremental FDA Alignment Regarding Its Biologics License Application For OST-HER2 For Prevention Or Delay Of Recurrence In Fully-Resected, Pulmonary Metastatic Osteosarcoma

OS Therapies Announces Full Alignment with UK MHRA and EU EMA for Conditional Marketing Authorisation Application Filing

OS Therapies Achieves Full Alignment With UK MHRA On Its Pending Conditional Marketing Authorization Application

OS Therapies Reports Strong Survival Data for Bone Cancer Treatment

OS Therapies Achieves Statistically Significant Benefit for OST-HER2-Treated Patients in Interim 3-Year Overall Survival Analysis of Phase 2b Pulmonary Metastatic Osteosarcoma Trial

OS Therapies Announces Statistically Significant Benefit For OST-HER2-Treated Patients In An Interim 3-Year Overall Survival Data Analysis

OS Therapies Provides OST-HER2 Metastatic Osteosarcoma Program Update and Announces Upcoming Conference Attendance